Ab-CPP-LSP-siRNA (cetuximab–PEG–LMWP–AANL–siRNA; ARC)
Sequence: VSRRRRGGRRRRRRAANL
siRNA (anti-EGFP; thiol-modified; Cy3/TAMRA labeled variants used for imaging)
| Experiment Id | EXP001975 |
|---|---|
| Paper | Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker me |
| Peptide | Ab-CPP-LSP-siRNA (cetuximab–PEG–LMWP–AANL–siRNA; ARC) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Defined by conjugate; compared at equal siRNA dose (100 nM). |
| Rna Concentration | 100 nM siRNA for all transfection groups (24 h treatment + 72 h incubation before readout). |
| Mixing Ratio | Covalent conjugate (ARC). |
| Formulation Format | Antibody–multifunctional peptide–siRNA covalent conjugate (ARC) |
| Formulation Components | Cetuximab linked to PEG–LMWP–AANL–anti-EGFP siRNA. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCT116-EGFP (EGFP stable transfectant human colon cancer cells) |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional RNA effect (EGFP silencing) by confocal + western blot |
| Output Value | ~85.7% EGFP protein silencing (western blot); strongest silencing among tested groups. |
| Output Units | |
| Output Notes | Activation via tumor enzyme legumain cleavage of AANL; antibody masks CPP during circulation in design concept. |
| Toxicity Notes | MTT assay in HCT116: ~90% viability at 125 nM; >75% up to 500 nM (siRNA-equivalent). |
| Curation Notes |